Foresee Pharmaceuticals Welcomes Positive CHMP Opinion Recommending Approval of CAMCEVI 21mg, 3-month strength in the European Union for Advanced Prostate Cancer
PR Newswire —
TAIPEI, March 6, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced that it has received notification from its licensing partner, Accord Healthcare, that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a...